BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bederra Corporation Announces Acquisition of Diagnos Inc. (ADK)


1/21/2008 8:56:15 AM

HOUSTON--(BUSINESS WIRE)--Bederra Corporation (Pink Sheets:BDRR) announces it has acquired the privately held Diagnos, Inc.

On or about December 27, 2007 Bederra Corporation completed the acquisition of Diagnos, Inc. in an all-stock transaction. Bederra Corporation issued 15 million restricted common shares of stock for the assets of Diagnosis, Inc.; Diagnos, Inc. will operate as a wholly owned subsidiary of Bederra Corporation. The financial statements issued by the company will reflect the combined financial results.

Diagnos, Inc., a privately held Texas Corporation, is located at 2000 N. Loop W., Suite 100, Houston, Texas, 77018. Diagnosis, Inc. was formed to provide medical diagnostic imaging services utilizing state of the art Positron Emission Tomography technology to detect Cancer, Alzheimer’s, Dementia and Heart Disease. The technology is so new there are only 18 machines in the Houston area serving a population of over 5 million. The technology is proven and accepted by Medicare and all private insurance carriers. The current medical disciplines that use this technology are oncology, neurology, cardiology, and urology.

Graham Williams, President of Bederra Corporation, states, “The acquisition of Diagnos, Inc. is the first of many medical related acquisitions planned to enhance our revenues in the coming years.” Projected gross revenues for fiscal year 2008 are anticipated to be in excess of $2.5 million dollars with profits.

Bederra Corporation issued 15 million restricted shares of common stock to the owners of Diagnosis, Inc.; as of December 31 2007, Bederra Corporation has 28,416,204 shares of common stock outstanding with 6 million shares in the public float.

Safe Harbor Statement

Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.

Contacts Bederra Corporation Graham Williams, 281-540-0500 President leasse@earthlink.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES